Diversifying Expression Platforms for Biopharmaceuticals and Industrial Enzymes

The advent of biotechnology in the last century has heralded a significant breakthrough with the development of recombinant biopharmaceuticals and industrial enzymes. These pioneering products are synthesized within eukaryotic or prokaryotic heterologous hosts, underscoring the adaptability of genetic engineering in their production. As our understanding of omics data expands, particularly regarding diverse heterologous hosts, and with the emergence of advanced genetic engineering tools, we gain the capability to artificially modify these hosts to enhance the production of recombinant proteins. This technological advancement is poised to propel the global market for recombinant products to unprecedented heights in the foreseeable future, underscoring the profound impact of these innovations across various industries. To fully leverage the potential of heterologous hosts in large-scale biosynthesis, it becomes imperative to discern their strengths and weaknesses. Scientists have identified bottlenecks in different hosts, and addressing these challenges is vital in meeting the escalating demand for recombinant products.